Emergent BioSolutions Inc. — Director's Dealing 2023

Mar 7, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Emergent BioSolutions Inc. (EBS)
CIK: 0001367644
Period of Report: 2023-03-02

Reporting Person: Glessner Coleen (EVP, Quality & Ethics, and CPL)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-03-02	Common Stock	A	3846	—	Acquired	111982	Direct
2023-03-02	Common Stock	A	7692	—	Acquired	119674	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-03-02	Employee Stock Options (Right to Buy)	$12.06	A	7692	Acquired	2030-03-01	Common Stock (7692.0)	Direct

Footnotes

F1: Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in two equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.

F2: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2023 and ending December 31, 2025, as certified by the Compensation Committee following the performance period. The amount reported is based on the target performance payout factor, or 100%.

F3: Vests in three equal installments beginning on the day prior to the anniversary date of the grant.

F4: Represents the corrected number of securities owned due to a computational error on prior Form-4.